Provided by Tiger Trade Technology Pte. Ltd.

Teva Pharmaceutical

30.82
-0.1400-0.45%
Post-market: 30.850.0300+0.10%19:53 EDT
Volume:4.28M
Turnover:131.88M
Market Cap:35.91B
PE:25.47
High:31.39
Open:31.26
Low:30.58
Close:30.96
52wk High:37.35
52wk Low:12.88
Shares:1.17B
Float Shares:1.14B
Volume Ratio:0.96
T/O Rate:0.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.21
EPS(LYR):1.21
ROE:20.79%
ROA:6.17%
PB:4.54
PE(LYR):25.47

Loading ...

Teva Pharmaceutical Credit Rating Raised by S&P, Moody's Upgrades Outlook

MT Newswires Live
·
Dec 24, 2025

Teva Pharmaceuticals Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Dec 22, 2025

Teva Pharmaceuticals Is Maintained at Buy by Goldman Sachs

Dow Jones
·
Dec 20, 2025

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

GlobeNewswire
·
Dec 19, 2025

BRIEF-Alvotech and Teva Secure U.S. Settlement Date For AVT06

Reuters
·
Dec 19, 2025

Alvotech Sa - License Entry Date for Avt06 in U.S. Set for Q4 2026

THOMSON REUTERS
·
Dec 19, 2025

Sagimet Biosciences Shares Rise on Licensing Agreement With Teva

Dow Jones
·
Dec 18, 2025

Teva Pharmaceuticals Is Maintained at Overweight by JP Morgan

Dow Jones
·
Dec 17, 2025

Teva Pharmaceuticals Is Maintained at Buy by B of A Securities

Dow Jones
·
Dec 10, 2025

Teva Pharmaceuticals Submits FDA Application for Monthly Schizophrenia Treatment

MT Newswires Live
·
Dec 09, 2025

Teva Pharmaceuticals Is Maintained at Buy by Goldman Sachs

Dow Jones
·
Dec 09, 2025

Teva Pharmaceuticals Initiated at Sector Outperform by Scotiabank

Dow Jones
·
Dec 05, 2025

Scotiabank Initiates Teva Pharmaceutical Industries With Sector Outperform Rating, $35 Price Target

MT Newswires Live
·
Dec 05, 2025

The Bull Case For Teva (TEVA) Could Change Following Launch Of Teva Rise Innovation Platform

Simply Wall St.
·
Dec 03, 2025

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Teva Pharmaceutical (TEVA)

TIPRANKS
·
Nov 27, 2025

Teva Pharmaceutical Industries (NYSE:TEVA): Evaluating Valuation After European Approval for Key Biosimilars

Simply Wall St.
·
Nov 27, 2025

Jefferies Sticks to Their Buy Rating for Teva Pharmaceutical (TEVA)

TIPRANKS
·
Nov 26, 2025

Teva Rise Innovation Platform Might Change The Case For Investing In Teva Pharmaceutical Industries (TEVA)

Simply Wall St.
·
Nov 26, 2025

Teva Pharmaceutical Says Denosumab Biosimilars Get European Commission Marketing Approval

MT Newswires Live
·
Nov 25, 2025

Teva, Amgen, Rithm, Fastly, Medtronic: Major Stock Moves!

TIPRANKS
·
Nov 22, 2025